GET DAILY SIGNALSHaleon (HLN) Reports +2.6% Organic Growth in Q3 2026, Trims Full-Year Guidance
Key Takeaways
- Haleon reported Q3 2026 organic revenue growth of +2.6%, below its own expectations, with reported revenue of £2.868 billion.
- Full-year 2026 organic revenue guidance was trimmed to around 2.5%, down from a previous 3%–5% range.
- Oral Health remained a bright spot, rising +8.8%, while Respiratory Health declined 2.0% on weak cold and flu consumption.
- A raw material classification change for Centrum over-the-counter (OTC) products in China weighed on performance, with no near-term resolution expected.
- The company announced an additional £500 million share buyback, while reaffirming high-single-digit adjusted operating profit growth at constant currency.
Earnings Context and Why It Matters
Haleon’s quarterly trading statement carries particular weight because the consumer healthcare company has been working to restore consistent volume growth while protecting margins. After delivering 3.1% organic growth in Q2 2026 and reaffirming its medium-term 4%–6% ambition, management entered Q3 expecting better momentum in North America and emerging markets. Instead, softer cold and flu demand and a regulatory classification shift in China interrupted that path. From what I see, the report tests whether the turnaround strategy can hold up against uneven category demand and whether long-term growth guidance remains credible.
Reported Results
For the third quarter of fiscal 2026, HLN posted organic revenue growth of 2.6%, driven by +2.1% price and +0.5% volume/mix. Reported revenue increased 2.5% to £2.868 billion. Regionally, North America grew 2.5% organically to £992 million, APAC rose 3.9% to £593 million, and International markets advanced 6.9% to £485 million. Europe slipped 0.6% to £798 million amid a challenging consumer environment.
Oral Health stood out with an 8.8% increase, while Respiratory Health fell 2.0% to £499 million due to subdued cold and flu demand. Management also highlighted a raw material classification change for Centrum OTC products in China as a headwind, with no short-term fix anticipated. Consequently, full-year organic revenue growth guidance was lowered to around 2.5% from the prior 3%–5% range. The company maintained its high-single-digit adjusted operating profit growth outlook at constant currency and announced a further £500 million share buyback. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
The market reacted sharply to the shortfall. HLN ADRs fell roughly 14.7% in premarket trading after the announcement, reflecting disappointment over the guidance cut and the China-related headwind. The revision from 3%–5% organic growth to around 2.5% signaled that the turnaround is taking longer than expected, especially in pain relief and respiratory categories. While the additional buyback and reaffirmed profit outlook provided some support, sentiment focused on concerns about growth durability and the ability to return to the medium-term range. The lack of a near-term resolution in China added to the caution.
Forward Outlook and Key Factors to Monitor
Looking ahead, I’m watching whether HLN can stabilize growth in the fourth quarter and into 2027. Management noted a favorable start to the U.S. cold and flu season, with category growth in the high teens over the past four weeks, but cautioned that the season is hard to predict and that roughly 70% of the cold and flu business lies outside the U.S.
The China classification issue remains a key variable. With no clear resolution path through 2027, the company is shifting its portfolio toward health food products and accelerating launches such as Benefiber in the fourth quarter. Investors should track how effectively these steps offset lost Centrum OTC sales.
Cost and margin execution will stay important. The company continues to expect high-single-digit adjusted operating profit growth at constant currency, backed by gross margin strength and supply chain productivity. Sustaining that profit growth while reinvesting in brands will be central to restoring confidence. Any updates on the medium-term 4%–6% growth ambition and progress in North America’s pain relief turnaround will draw close attention in coming quarters.
Exploring AI Tools for Stock Research
When analyzing names like HLN, I often rely on Tickeron’s AI Screener to quickly scan for technical patterns, fundamentals, and performance metrics across the consumer healthcare sector. This helps surface comparable ideas and contextualize results without manual effort.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
HLN in -1.96% downward trend, declining for three consecutive days on October 28, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where HLN declined for three days, in 117 of 220 cases, the price declined further within the following month. The odds of a continued downward trend are 53%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for HLN moved out of overbought territory on October 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 13 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 46%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 27 of 54 cases where HLN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 50%.
HLN broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for HLN entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 08, 2026. You may want to consider a long position or call options on HLN as a result. In 44 of 72 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 61%.
The Moving Average Convergence Divergence (MACD) for HLN just turned positive on October 08, 2026. Looking at past instances where HLN's MACD turned positive, the stock continued to rise in 21 of 35 cases over the following month. The odds of a continued upward trend are 60%.
HLN moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for HLN crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 5 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 33%.
Following a +0.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where HLN advanced for three days, in 138 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 53%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. HLN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.685) is normal, around the industry mean (8.801). P/E Ratio (27.322) is within average values for comparable stocks, (-2.500). Projected Growth (PEG Ratio) (2.158) is also within normal values, averaging (2.152). Dividend Yield (0.026) settles around the average of (0.044) among similar stocks. P/S Ratio (2.739) is also within normal values, averaging (178.797).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HLN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric
Advertisement